Muglia Named to Institute of Medicine
Louis Muglia, MD, PhD, professor of pediatrics, has been elected to membership in the prestigious Institute of Medicine (IOM) of the National Academy of Sciences.
New IOM members are elected by current active members through a highly selective process that recognizes individuals who have made major contributions in the advancement of the medical sciences, health care and public health. Muglia takes his place alongside 70 other newly elected members this year.
Muglia serves as director of the Cincinnati Childrens Hospital Medical Center Center for Prevention of Preterm Birth and co-director of the Perinatal Institute. He has pioneered the in vivo analyses of regulation of the endocrine stress response and the molecular pathways leading to birth.
Read more about Muglia at cincinnatichildrens.org/news/release/2013/muglia-named-to-institute-of-medicine/.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.